Disease-modifying antirheumatic drugs including methotrexate, biologics, and Janus kinase inhibitors, aggregated by pharmaceutical wholesalers for B2B sales to hospital networks, rheumatology groups, and long-term care facilities procuring therapies for autoimmune joint disease management.